touchREVIEWS in Oncology & Haematology

VOLUME 20 • ISSUE 1 • 2024
EDITOR-IN-CHIEF: AXEL S MERSEBURGER

A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non–Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy
Miguel García-Pardo and Pilar Garrido

Dostarlimab for the Treatment of Endometrial Cancer: A Review
Chelsea E Stewart and Dana Chase

Immunotherapeutic Advances in the Treatment of Merkel Cell Carcinoma
Ruben J Cruz-Chamorro, Alberic Gan, John M Bryant and Evan Wuthrick

Trastuzumab Deruxtecan for the Treatment of HER2-low Advanced or Metastatic Breast Cancer
Toshinari Yamashita

www.touchONCOLOGY.com

eISSN: 2752-5481

touchREVIEWS
in Oncology & Haematology

Volume 20 • Issue 1 • 2024

Cover image: Cancer cells
By Crystal light | © stock.adobe.com



touchREVIEWS in Oncology & Haematology wishes to thank the organizations below for their assistance. This does not constitute any official endorsement.

Senior Editorial Director
Gina Furnival

Editorial Directors
Katey Gabrysch
Carla Junkier
Sophie Nickelson

Editorial Workflow
Heather Hall

Head of Medical & Editorial
Nicola Cartridge
E: nicola.cartridge@touchmedicalmedia.com
T: +44 (0)20 7193 3186

CEO & Managing Director
Barney Kent
E: barney.kent@touchmedicalmedia.com
T: +44 (0)20 7193 3009

Head of Strategic Partnerships
Caroline Markham
E: caroline.markham@touchmedicalmedia.com
T: +44 (0)20 7193 3704

All information obtained by Touch Medical Media and each of the contributors from various sources is as current and accurate as possible. However, due to human or mechanical errors, Touch Medical Media and the contributors cannot guarantee the accuracy, adequacy or completeness of any information, and cannot be held responsible for any errors or omissions, or for the results obtained from the use thereof. Where opinion is expressed, it is that of the authors and does not necessarily coincide with the editorial views of Touch Medical Media. Statistical and financial data in this publication have been compiled on the basis of factual information and do not constitute any investment advertisement or investment advice. For the avoidance of doubt, the information contained in this publication is intended for use by licensed medical professionals. The content should not be considered medical advice, diagnosis or treatment recommendations.

© 2024 Touch Medical Media Services Limited, a private limited company registered in England and Wales at Lancashire Gate, 21 Tiviot Dale, Stockport, Cheshire, SK1 1TD with registered number 12930327. All rights reserved.

eISSN: 2752-5481

touch™ MEDICAL MEDIA

www.touchmedicalmedia.com

touchREVIEWS
in Oncology & Haematology

Editors-in-Chief

Axel S Merseburger
Department of Urology, Campus Lübeck, University Hospital Schleswig-Holstein, Lübeck, Germany

Matti S Aapro
Multidisciplinary Oncology Institute, Genolier, Switzerland

Eleni Andreopoulou
University of Texas MD Anderson Cancer Center, Houston, TX, USA

Paolo A Ascierto
Unit of Melanoma, ational Tumor Institute 'Fondazione G Pascale', Naples, Italy

John L Marshall
Lombardi Comprehensive Cancer Center, Washington, DC, USA

David G Mutch
Washington University School of Medicine, St Louis, MO, USA

Maurice Pérol
Thoracic Oncology, Medical Oncology Department of Léon Bérard Cancer Center, Lyon, France

Editorial Board

Mohammad Ammad-Ud-Din
Rochester General Hospital, Rochester, NY, USA

Ahmad Awada
Medical Oncology Clinic, Jules Bordet Institute, Brussels, Belgium

Wadie F Bahou
State University of New York, Stony Brook, NY, USA

Tanios Bekaii-Saab
Mayo Clinic, Phoenix, AZ, USA

Raffaele Califano
Department of Medical Oncology, The Christie NHS Foundation Trust, Manchester, UK

Ezra Cohen
University of Chicago Medical Center, Georgetown University, Chicago, IL, USA

Jorge Cortes
Georgia Cancer Center, Augusta University, Augusta, GA, USA

Véronique Diéras
Department of Medical Oncology, Centre Eugène Marquis, Rennes, France

Massimo Dominici
Medical Oncology, University Hospital of Modena, Modena, Italy

Martin J Edelman
Fox Chase Cancer Center, Philadelphia, PA, USA

Dean A. Fennell
Leicester Cancer Research Centre, Genetics & Genome Biology, University of Leicester, UK

Willem E Fibbe
Department of Immuno-haematology and Blood Transfusion, Leiden University Medical Center, Leiden, Netherlands

Robin Foà
Institute of Hematology, 'La Sapienza' University of Rome, Rome, Italy

Michael K Gibson
Vanderbilt University Medical Center, Vanderbilt-Ingram Cancer Center, Nashville, TN, USA

Charlie Gourley
Cancer Research UK Edinburgh Center; Nicola Murray Centre for Ovarian Cancer Research, The University of Edinburgh, Scotland, UK

Axel Grothey
West Cancer Center, Germantown, TN, USA

Martin Hutchings
The Finsen Centre, National Hospital, Copenhagen University Hospital, Copenhagen, Denmark

Claudine Isaacs
Lombardi Comprehensive Cancer Center, Georgetown University, Chicago, IL, USA

Elias Jabbour
University of Texas MD Anderson Cancer Center, Houston, TX, USA

Ken Kato
National Cancer Center Hospital, Tokyo, Japan

Daniel Kelly
Royal College of Nursing, School of Healthcare Sciences, Cardiff University, Cardiff, UK

Ticiana Leal
Emory University School of Medicine, Atlanta, GA, USA

Charles D Lopez
Oregon Health & Science University, Portland, OR, USA

Domenica Lorusso
Catholic University of Rome, Rome, Italy

Mario Mandalà
Department of Oncology and Haematology, Papa Giovanni XXIII Cancer Center Hospital, Bergamo, Italy

Pier Mannuccio Mannucci
Maggiore University Hospital of Mila; Angelo Bianchi Bonomi Haemophilia and Thrombosis Centre, Milan, Italy

John L Marshall
MedStar Georgetown University Hospital, Washington, DC, USA

Bruce Minsky
University of Texas MD Anderson Cancer Center, Houston, TX, USA

Michael J Morris
Memorial Sloan Kettering Cancer Center, New York, NY, USA

Suchita Pakkala
Emory University School of Medicine, Atlanta, GA, USA

Bernardo Rapoport
The Medical Oncology Centre of Rosebank, Johannesburg, South Africa

Andrew I Schafer
Weill Cornell Medical College, New York, NY, USA

Emma Searle
The Christie Hospital NHS Foundation Trust, Manchester, UK

Lena Sharp
Regional Cancer Center, Stockholm, Sweden

Gerard Socié
Department of Bone Marrow Transplantation, Hospital Saint-Louis, Paris, France

Sara M Tolaney
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA

Ulka Vaishampayan
Wayne State University, Detroit, MI, USA

Benjamin Weinberg
Ruesch Center for the Cure of Gastrointestinal Cancers; Lombardi Comprehensive Cancer Center, Washington, DC, USA

Antoinette J Wozniak
Wayne State University; Barbara Ann Karmanos Cancer Institute, Detroit, MI, USA

touchREVIEWS
in Oncology & Haematology

Established: January 2005 **Frequency**: Bi-annual
Current edition: Volume 20 Issue 1, 2024

Aims and scope
- *touchREVIEWS in Oncology & Haematology* enables time-pressured physicians to stay abreast of major advances and opinions in oncology and haematology practice.
- *touchREVIEWS in Oncology & Haematology* comprises balanced and comprehensive articles written by leading authorities, addressing the most important and salient developments in the oncology and haematology fields.
- *touchREVIEWS in Oncology & Haematology* endeavours to support physicians, clinicians and related healthcare professionals in continuously developing their knowledge, effectiveness and productivity. The editorial policy has been designed to encourage discussion among this peer group.
- Comprehensive bibliographies for each article mean that *touchREVIEWS in Oncology & Haematology* is an informative and valuable reference tool for use throughout the year.
- All articles are subject to peer review, and must adhere to the ICJME, GPP 2022, and COPE guidelines.

Structure and format
- *touchREVIEWS in Oncology & Haematology* is a peer-reviewed, free-to-access, bi-annual journal comprising review articles, editorials, special reports and original research.
- The structure of each edition of the publication comprises section categories determined by the Editor. The degree of coverage assigned to each category is the decision of the Editor, and in part reflects the views of the Editorial Board.
- All articles state any author disclosures along with any funding, financial support and/or medical writing assistance.
- Each edition of *touchREVIEWS in Oncology & Haematology* is published in full, online at: www.touchONCOLOGY.com

Editorial expertise
touchREVIEWS in Oncology & Haematology is supported by various levels of expertise:
- Guidance from an Editorial Board consisting of leading authorities from a variety of oncology and haematology disciplines.
- Invited contributors who are recognized authorities in their respective fields.
- Peer review – conducted by experts appointed for their experience and knowledge of a specific topic.
- An experienced team of editors and technical editors.

Peer review
- On submission, all articles are assessed by the Editor to determine their suitability for inclusion and appropriateness for peer review.
- The Editor identifies appropriate reviewers, who are selected on the basis of their specialist knowledge in the relevant area, following consultation with a member of the Editorial Board where necessary.
- We aim to have the final peer review decision within 4 weeks.
- Following review, papers are either accepted without modification, returned to the author(s) to incorporate required changes, or not accepted for publication.
- The Editor reserves the right to accept or reject any proposed amendments on the advice of the Editorial Board and reviewers.

Submissions and instructions for authors
- The Editor commissions articles with guidance from the Editorial Board and unsolicited articles are welcomed.
- The Editor is always keen to hear from authors wishing to discuss potential submissions, and will give due consideration to any proposals. Please contact the Editor for further details: editorialmanager@touchmedicalmedia.com
- Instructions for authors are available on the website: www.touchONCOLOGY.com

Distribution and readership
touchREVIEWS in Oncology & Haematology is distributed globally, on a bi-annual basis, through controlled circulation to senior professionals in the field globally.

Free-to-access
All articles are free-to-access, which allows anyone in the oncology and haematology field to download published articles free of charge.

Abstracting and indexing
touchREVIEWS in Oncology & Haematology is abstracted, indexed and listed in Embase, EBSCO, Genamics JournalSeek, Google Scholar, IndexCopernicus and Summon by Serial Solutions.

Copyright
Authors transfer copyright of their article to Touch Medical Media, who publish the article as free-to-access to registered users.

Online resources
www.touchmedicalmedia.com provides clinicians and other industry professionals with a free resources across nine therapy areas including cardiology, endocrinology, haematology, immunology, infectious diseases, neurology, oncology, ophthalmology and respiratory and pulmonary medicine.

Society partners
touchONCOLOGY has developed very valuable partnerships with the most respected not-for-profit medical societies both in Europe and the USA. These partnerships are key as touchONCOLOGY.com helps to promote awareness of these medical societies whilst also providing free-to-access, peer-reviewed articles and multimedia content to society members, which ensures that the industry is kept up to date with the latest cutting-edge content and opinion from world-renowned doctors.

About Touch Medical Media
Touch Medical Media publishes a rich and diverse portfolio of free-to-access, peer-reveiwed journals across the clinical and pharmaceutical arenas. Touch Medical Media aims to assist in the education and practice of healthcare and pharmaceutical professionals.

touch™ ONCOLOGY

Contents



Foreword

1 **Foreword**
Axel Merseburger
Department of Urology, Universitätsklinikum Schleswig-Holstein, Campus Lübeck, Germany

Editorial

Gastrointestinal Cancers

2 **Long-term Survival in Patients with Advanced Hepatocellular Cancer with Dual Immunotherapy Agents: Tremelimumab Plus Durvalumab**
Amit Mahipal,[1] Kanchi Patell[1] and Richard Kim[2]
1. Department of Oncology, University Hospitals Seidman Cancer Center, Case Western Reserve University, Cleveland, OH, USA; 2. Department of GI Oncology, H. Lee Moffitt Cancer Center, Tampa, FL, USA

Lung Cancer

5 **A New Frontier in the Treatment of Epidermal Growth Factor Receptor-mutated Non–Small-Cell Lung Cancer: Amivantamab-vmjw and Chemotherapy**
Miguel García-Pardo and Pilar Garrido
Department of Medical Oncology, Hospital Universitario Ramón y Cajal, Madrid, Spain

Reviews

Gynaecological Cancers

9 **Dostarlimab for the Treatment of Endometrial Cancer: A Review**
Chelsea E Stewart and Dana Chase
Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, University of California Los Angeles, Los Angeles, CA, USA

Gastrointestinal Cancers

12 **Futibatinib for the Treatment of Previously Treated, Unresectable, Locally Advanced or Metastatic Intrahepatic Cholangiocarcinoma with Fibroblast Growth Factor Receptor 2 (FGFR2) Gene Fusions or Other Rearrangements**
Valerie Crolley and John Bridgewater
University College London Cancer Institute, London, UK

20 **Fruquintinib in Patients with Previously Treated Metastatic Colorectal Cancer**
Tiago Biachi de Castria,[1,2] Ruoyu Miao[1,2] and Richard D Kim[1,2]
1. Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2. Morsani College of Medicine, University of South Florida, Tampa, FL, USA

touch™ ONCOLOGY

Contents



Leukaemia

25 **Olutasidenib for Adults with Relapsed or Refractory Acute Myeloid Leukaemia with Isocitrate Dehydrogenase 1 Mutation**

Florence Pasquier and Stéphane De Botton

Département d'Hématologie, Gustave Roussy, Université Paris-Saclay, Villejuif, France

Dermatological Cancers

32 **Immunotherapeutic Advances in the Treatment of Merkel Cell Carcinoma**

Ruben J Cruz-Chamorro,[1] Alberic Gan,[2] John M Bryant[1] and Evan Wuthrick[1]

1. Department of Radiation Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA; 2. Morsani College of Medicine, University of South Florida, Tampa, FL, USA

Breast Cancer

36 **Trastuzumab Deruxtecan for the Treatment of HER2-low Advanced or Metastatic Breast Cancer**

Toshinari Yamashita

Department of Breast Surgery and Oncology, Kanagawa Cancer Center, Yokohama, Japan

touch™ ONCOLOGY